These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Psychedelic drugs-a new era in psychiatry? . Nutt D Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488 [TBL] [Abstract][Full Text] [Related]
6. Psilocybin and MDMA for the treatment of trauma-related psychopathology. Bird CIV; Modlin NL; Rucker JJH Int Rev Psychiatry; 2021 May; 33(3):229-249. PubMed ID: 34121583 [TBL] [Abstract][Full Text] [Related]
7. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR Pharmacol Ther; 2022 Nov; 239():108195. PubMed ID: 35489438 [TBL] [Abstract][Full Text] [Related]
8. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Bahji A; Forsyth A; Groll D; Hawken ER Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109735. PubMed ID: 31437480 [TBL] [Abstract][Full Text] [Related]
10. How ecstasy and psilocybin are shaking up psychiatry. Tullis P Nature; 2021 Jan; 589(7843):506-509. PubMed ID: 33505033 [No Abstract] [Full Text] [Related]
12. [Psychedelics in the treatment of PTSD]. Vermetten E; Krediet E; Bostoen T; Breeksema JJ; Schoevers RA; van den Brink W Tijdschr Psychiatr; 2020; 62(8):640-649. PubMed ID: 32816292 [TBL] [Abstract][Full Text] [Related]
13. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Schmid Y; Gasser P; Oehen P; Liechti ME J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials. Yang J; Wang N; Luo W; Gao J Psychiatry Res; 2024 Sep; 339():116043. PubMed ID: 38896930 [TBL] [Abstract][Full Text] [Related]
15. Analysis of recreational psychedelic substance use experiences classified by substance. Hase A; Erdmann M; Limbach V; Hasler G Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816 [TBL] [Abstract][Full Text] [Related]
16. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. Zeifman RJ; Kettner H; Ross S; Weiss B; Mithoefer MC; Mithoefer AT; Wagner AC Eur J Psychotraumatol; 2024; 15(1):2297536. PubMed ID: 38174611 [TBL] [Abstract][Full Text] [Related]
17. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331 [TBL] [Abstract][Full Text] [Related]
18. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics. Nogrady B BMJ; 2023 Jul; 382():1599. PubMed ID: 37433614 [No Abstract] [Full Text] [Related]
19. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Haridy R Nature; 2023 Jul; 619(7969):227-228. PubMed ID: 37386185 [No Abstract] [Full Text] [Related]
20. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. Amoroso T J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]